Effects of ketogenic diet on cognitive impairment in older adults: a systematic review and meta-analysis.

Arch Gerontol GeriatrSep 12, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Lining Xi, Junli Wan, Yan Hua et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of ketogenic diet (KD) on cognitive impairment in older adults, analyzing 12 randomized controlled trials with 707 participants. The study found that KD-related dietary strategies significantly improved overall cognitive function (SMD = 0.34, p < 0.01), particularly in memory and language functions, while also enhancing ketone body production.

Key findings

  • KD-related dietary strategies improved overall cognitive function (SMD = 0.34, p < 0.01).
  • Significant improvements in memory were observed (SMD = 0.53, p = 0.01).
  • Language function also showed significant enhancement (SMD = 0.43, p = 0.002).
  • KD increased acetoacetate and β-hydroxybutyrate concentrations, indicating effective ketone production.

Why it matters

Cognitive impairment in older adults can lead to significant functional decline. This study suggests that ketogenic dietary strategies may offer a potential intervention to improve cognitive outcomes, which could alleviate care burdens associated with cognitive decline.

Source

PubMed · PMID 42753449

Published in Arch Gerontol Geriatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.